Antibody Production Market Global Industry Share, Size, Future Demand, Global Research, Top Leading Players, Region by Forecast to 2026

    163

    Summary

    Antibody Production Market was valued at US$9.93 billion in the year 2018 and is expected to reach US$23.22 billion by 2026, at a CAGR of 12.29%.

    Press Release

     

     

    Antibodies are protein molecules resembling the alphabet ‘Y’. They are innately produced by plasma cells as a primary response and also produced by B cells. They are a part of the immune system that protects against toxins, antigens, and pathogens such as bacteria and viruses. When an antigen or an organism enters the body, the macrophages present them to B cells. The B cells codes for a new antibody containing an antigen-binding site that is specific to the epitope of the antigen. The antibodies are then released to the bloodstream and B cells produce the same type of antibodies if they encounter with the same antigen once again.

     

    The spotlight on antibodies arose due to its high specificity towards the targeted cells while sparing the normal cells. The antibodies can be custom-made against a particular epitope through hybridoma technology. The antibodies which target one epitope are monoclonal antibodies (mAbs) whereas antibodies targeting multiple epitopes are denoted as polyclonal antibodies. The ability to produce antibodies by connecting to specific antigens is used in manufacturing probes that have the capability of identifying specific molecules and can be used across a spectrum of research and diagnostic purposes.

     

    With more inclination towards targeted antibody therapy, and with biotechnology and biopharmaceutical companies focusing more on antibody production for specific requirements, the market is set to grow at a CAGR of 12.29% during the forecast period.

    Rising geriatric population around the world, increase in the prevalence of infectious and disorders such as cancer, rheumatoid arthritis, and other chronic diseases, more and more interest towards targeted therapy are driving the antibody production market. Also, there is a steep surge in the antibody production due to an increase of biotechnology and biopharmaceutical organizations investing more funds in research and development owing to develop advanced biologics and therapeutics with a principal focus on monoclonal antibodies. However, an increase in the number of local players, cost of the therapy and failure during approvals are the factors which may likely hamper the market growth.

     

     

     

    Contact

    Optima Insights

    Mr Chucks G

    +91 966 6620 365 (Asia) | +1 424 2554 365 (US)

    Email:[email protected]

    https://www.optimainsights.org